z-logo
open-access-imgOpen Access
Core–shell‐type polymer–lipid nanoparticles for the transdermal delivery of daidzein
Author(s) -
Wusiman Zaitongguli,
Sun Liang,
Zuo Tiantian,
Yin Yunzhi,
Yang Xiaoming,
Shen Qi
Publication year - 2018
Publication title -
micro and nano letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.25
H-Index - 31
ISSN - 1750-0443
DOI - 10.1049/mnl.2018.5095
Subject(s) - azone , transdermal , nanoparticle , chemistry , polymer , penetration (warfare) , solid lipid nanoparticle , permeation , lecithin , chromatography , chemical engineering , materials science , nanotechnology , organic chemistry , pharmacology , biochemistry , medicine , operations research , membrane , engineering
Daidzein (DZ) is an ideal Chinese herb for treating cardiocerebrovascular disease. Despite its poor water solubility and limited application, DZ was successfully loaded, along with penetration enhancer azone, onto core–shell‐type polymer–lipid nanoparticles through a two‐step preparation method. The mean particle diameter, encapsulation efficiency, and drug‐loading rate of DZ–polymer‐azone–lipid nanoparticles (D‐P‐Azone‐LNs) were 77.59 ± 2.26 nm, 79.91% ± 1.46%, and 1.50% ± 0.02%, respectively. In skin penetration experiment, the cumulative amount of DZ from D‐P‐Azone‐LN reached 14.91 μg·cm −2 at 72 h. This amount was 1.44 and 6.01 times higher than those of DZ–polymer–lipid nanoparticles (D‐P‐LNs) and DZ solution, respectively. Confocal laser scanning microscopy was used to conduct a qualitative analysis. In vivo study, D‐P‐Azone‐LN achieved better skin retention than those of D‐P‐LN and DZ. Furthermore, no significant irritation was observed in the skin irritation experiment. These results suggested that the core–shell polymer–lipid nanoparticles, which combined the properties of polymer and lipid nanoparticles, can offer a useful formulation for enhancing the skin permeation of drug for transdermal delivery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here